Integra lifesciences (NASDAQ:IART) VP Joseph Vinhais sold 6,800 shares of the company’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $54.13, for a total value of $368,084.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
IART traded down $1.35 during trading on Friday, reaching $54.59. 538,045 shares of the company were exchanged, compared to its average volume of 517,298. The stock has a market capitalization of $4,395.68, a price-to-earnings ratio of 28.14, a price-to-earnings-growth ratio of 1.73 and a beta of 0.65. The company has a debt-to-equity ratio of 1.85, a quick ratio of 1.51 and a current ratio of 2.36. Integra lifesciences has a 12-month low of $40.59 and a 12-month high of $58.17.
Integra lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. The business had revenue of $368.60 million for the quarter, compared to analysts’ expectations of $362.64 million. Integra lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The firm’s quarterly revenue was up 44.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 EPS. research analysts forecast that Integra lifesciences will post 2.33 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of IART. First Trust Advisors LP lifted its holdings in Integra lifesciences by 216.1% during the 3rd quarter. First Trust Advisors LP now owns 51,084 shares of the life sciences company’s stock worth $2,579,000 after purchasing an additional 34,925 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Integra lifesciences during the 3rd quarter valued at about $619,000. Stevens Capital Management LP purchased a new position in shares of Integra lifesciences during the 3rd quarter valued at about $647,000. Prudential Financial Inc. raised its holdings in shares of Integra lifesciences by 3.3% during the 3rd quarter. Prudential Financial Inc. now owns 105,836 shares of the life sciences company’s stock valued at $5,343,000 after buying an additional 3,340 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Integra lifesciences by 3.1% during the 3rd quarter. Principal Financial Group Inc. now owns 489,221 shares of the life sciences company’s stock valued at $24,696,000 after buying an additional 14,833 shares in the last quarter. 90.93% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Joseph Vinhais Sells 6,800 Shares of Integra lifesciences (IART) Stock” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://baseballnewssource.com/2018/04/06/integra-lifesciences-holdings-corp-iart-vp-sells-368084-00-in-stock/2037327.html.
About Integra lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.